Showing 1971-1980 of 2659 results for "".
- Iantrek Presents New Data for CycloPen System with AlloFlo Carriershttps://modernod.com/news/iantrek-presents-new-data-for-cyclopen-system-with-alloflo-carriers/2482249/At the ASCRS meeting in Boston, Iantrek presented new data for its micro-interventional glaucoma surgical device CycloPen with AlloFlo. CycloPen is Iantrek’s microinterventional system for the ab-interno construction, modification, reinforcement and repair of a cyclodialysis.
- RevOpsis Secures $16.5 Million Seed Funding to Advance First-in-Class Tri-Specific Therapy for Wet AMD Treatmenthttps://modernod.com/news/revopsis-secures-165-million-seed-funding-to-advance-first-in-class-tri-specific-therapy-for-wet-amd-treatment/2482246/RevOpsis Therapeutics announced it has successfully closed its first seed funding round, raising $16.5 million to develop and commercialize treatments for chronic multifactorial diseases through the company's fully human multispecific proprietary Rev-Mod Platform. The 
- New Ocular Telehealth Program Enables Diabetic Retinopathy Screeninghttps://modernod.com/news/new-ocular-telehealth-program-enables-diabetic-retinopathy-screening/2482241/Visionix USA and 20/20NOW have launched an ocular telehealth program to enable diabetic retinopathy screening. The new technology will be presented at the American Telemedicine Association (ATA)’s 2024 Nexus Conference and Expo in Arizona in May. Visionix and 20/20NOW will be offe
- In Japanese Study, Vabysmo Achieves Primary Endpoint in Phase 3 Study for Angioid Streakshttps://modernod.com/news/in-japanese-study-vabysmo-achieves-primary-endpoint-in-phase-3-study-for-angioid-streaks/2482231/Japan-based Chugai Pharmaceutical announced that the Japanese phase 3 study (NIHONBASHI study), evaluating Roche and Genentech's Vabysmo (faricimab) for angioid streaks associated with neovascularization, met its primary endpoint, demonstrating statistically signific
- Orbis Partners and Heidelberg Engineering Partner to Train Eye Care Professionals Around the Worldhttps://modernod.com/news/orbis-partners-with-heidelberg-engineering-to-train-eye-care-professionals-around-the-world/2482223/Orbis has announced a new partnership with Heidelberg Engineering, which will fund teaching opportunities and research focused on training eye care professionals around the world via Cybersight—Orbis’s award-winning telemedicine and e-learning platform. It will als
- FDA Approves Ocugen's IND Amendment to Initiate Phase 3 Trial for RP Gene Therapyhttps://modernod.com/news/fda-approves-ocugens-ind-amendment-to-initiate-phase-3-trial-for-rp-gene-therapy/2482220/Ocugen announced that the FDA has cleared the company’s investigational new drug (IND) amendment to initiate a phase 3 clinical trial of OCU400, a modifier gene therapy product candidate being developed for retinitis pigmentosa (RP). “The initiation of the OCU400 phase
- Aviceda Therapeutics Announces Formation of European Clinical Advisory Boardhttps://modernod.com/news/aviceda-therapeutics-announces-formation-of-european-clinical-advisory-board/2482218/Aviceda Therapeutics announced the formation of its European Clinical Advisory Board (CAB) made up of internationally recognized thought leaders in retina. The CAB will provide strategic consultation on the company’s clinical development of its lead asset, AVD-104, for the treatment of geog
- Sight Sciences Announces the Results of the 3-Year Prospective GEMINI Trial and the Cross-Over Phase of the SAHARA RCThttps://modernod.com/news/sight-sciences-announces-the-results-of-the-3-year-prospective-gemini-trial-and-the-cross-over-phase-of-the-sahara-rct/2482205/Sight Sciences announced that data from studies of two of its proprietary glaucoma and dry eye technologies, the OMNI Surgical System and the TearCare System, will be presented in two oral presentations and two posters at this year’s ASCRS annual meeting, April 5-8, 
- Aurion Biotech to Present Clinical Data at ASCRShttps://modernod.com/news/aurion-biotech-to-present-clinical-data-at-ascrs/2482204/Aurion Biotech announced several presentations during the 2024 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting to be held April 5-8, 2024 in Boston. At Eyecelerator and ASCRS, data will be presented from the company’s Escal&
- Centricity Vision to Present at ASCRS and Eyeceleratorhttps://modernod.com/news/centricity-vision-to-present-at-ascrs-and-eyecelerator/2482203/Centricity Vision announced that it will present on its recently launched ZEPTOLink IOL Positioning System during the 2024 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting to be held April 5-8, 2024 in Boston. Additionally, Leonard Borrmann, the company’s newl